Natera (NTRA) On Prospera Coverage Expansion And Revenue Strength Looks Fully Valued

Simply Wall St.07-18

Natera (NTRA) stock is in focus after two key developments: a final local coverage determination expanding Prospera transplant test access and stronger than expected revenue growth supported by higher...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652392231?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-18 15:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652392231","market":"sg","top_or_hot":-1,"title":"Natera (NTRA) On Prospera Coverage Expansion And Revenue Strength Looks Fully Valued","media":"Simply Wall St.","content":"<div>\n<p>Natera (NTRA) stock is in focus after two key developments: a final local coverage determination expanding Prospera transplant test access and stronger than expected revenue growth supported by higher...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/natera-ntra-on-prospera-coverage-expansion-and-revenue-stren\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natera (NTRA) On Prospera Coverage Expansion And Revenue Strength Looks Fully Valued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatera (NTRA) On Prospera Coverage Expansion And Revenue Strength Looks Fully Valued\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-18 15:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/natera-ntra-on-prospera-coverage-expansion-and-revenue-stren><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Natera (NTRA) stock is in focus after two key developments: a final local coverage determination expanding Prospera transplant test access and stronger than expected revenue growth supported by higher...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/natera-ntra-on-prospera-coverage-expansion-and-revenue-stren\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/natera-ntra-on-prospera-coverage-expansion-and-revenue-stren","article_id":"2652392231","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/natera-ntra-on-prospera-coverage-expansion-and-revenue-stren","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2652392231","pubTimestamp":1784359749,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Natera (NTRA) stock is in focus after two key developments: a final local coverage determination expanding Prospera transplant test access and stronger than expected revenue growth supported by higher testing volumes.\nSee our latest analysis for Natera.\nNatera’s recent developments appear to be reflected in its share price, with a 30.2% 90 day share price return and a very large 3 year total shareholder return that suggests momentum has been building over a longer period.\nIf Natera’s move has...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc."},"translate_title":"Natera (NTRA) 谈 Prospera 覆盖范围扩张和收入实力看起来得到了充分重视","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1.5},"content_text":"Natera (NTRA) stock is in focus after two key developments: a final local coverage determination expanding Prospera transplant test access and stronger than expected revenue growth supported by higher testing volumes. See our latest analysis for Natera. Natera’s recent developments appear to be reflected in its share price, with a 30.2% 90 day share price return and a very large 3 year total shareholder return that suggests momentum has been building over a longer period. If Natera’s move has caught your attention, this could be a good moment to look at other healthcare testing and diagnostics plays using the 39 healthcare AI stocks After a 30.2% 90 day run and a very large 3 year shareholder return, the key issue now is whether recent LCD progress and revenue strength leave Natera with meaningful upside ahead, or if most of the easy gains are already in the price. AdvertisementMost Popular Narrative: 4% Overvalued The most followed narrative puts Natera’s fair value at $260.05, slightly below the last close of $271.39. This sets up a tight valuation debate.  Increasing adoption and acceptance of advanced molecular diagnostics is driving sustained volume and revenue growth across Natera's diversified portfolio, with significant headroom remaining for further penetration, particularly in oncology (Signatera) and organ health (Prospera). This will likely boost top-line revenue.  Read the complete narrative. Curious what justifies paying above that fair value line for Natera? The narrative leans heavily on compounding revenue, rising margins and a premium profit multiple usually reserved for market leaders. Result: Fair Value of $260.05 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there is still the risk that Natera’s heavy spending and intense MRD competition could limit the margin gains and premium multiples implied in the current narrative. Find out about the key risks to this Natera narrative. Another View: SWS DCF Points to Undervaluation The first narrative argues Natera looks around 4% overvalued versus a $260.05 fair value. Yet the SWS DCF model suggests something very different, with an estimated future cash flow value of $559.54 per share, implying the current $271.39 price sits well below that level. Which story do you think fits your own expectations for Natera’s cash generation and risk? Look into how the SWS DCF model arrives at its fair value. NTRA Discounted Cash Flow as at Jul 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Natera for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With such a mixed picture around Natera, it makes sense to move quickly, review the underlying data, and decide where you stand on the 2 key rewards and 1 important warning sign Looking for more investment ideas beyond Natera? If Natera has sharpened your focus on where capital goes next, do not stop here. Broaden your watchlist now with targeted stock ideas before others get there first.  Target resilience by reviewing companies highlighted in the 84 resilient stocks with low risk scores to see which stocks score well on downside protection. Hunt for potential value by scanning the 47 high quality undervalued stocks and spot stocks that combine quality fundamentals with prices that differ from intrinsic estimates. Strengthen your core holdings by using the solid balance sheet and fundamentals stocks screener (47 results) to identify companies with financial profiles designed to handle tougher conditions.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Natera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652392231","isCrawlerRequest":true}